Search research articles
Contact Us
Filters
Showing results (21-30 of 97) with videos related to
Page
of 10
Sort By:
Cancer Genomics & Proteomics
|
November 20, 2012
Genetically engineered fusion proteins for treatment of cancer
Ulrich H Weidle, Britta Schneider, Guy Georges, et al.
Cancer Genomics & Proteomics
|
December 28, 2018
The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs
Ulrich H Weidle, Alexandra Epp, Fabian Birzele, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 17, 2015
Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles
Irmgard S Thorey, Michael Grote, Klaus Mayer, et al.
Mabs
|
August 21, 2010
Fluorescent Citrine-IgG fusion proteins produced in mammalian cells
Alexander K Haas, Christoffer von Schwerin, Daniela Matscheko, et al.
Nature Reviews. Drug Discovery
|
March 6, 2024
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M Reichert, et al.
Expert Opinion on Biological Therapy
|
April 23, 2004
Development of secreted proteins as biotherapeutic agents
Angelika L Bonin-Debs, Irene Boche, Hendrik Gille, et al.
Biomolecules
|
April 27, 2024
Functional Integrity of Radical SAM Enzyme Dph1•Dph2 Requires Non-Canonical Cofactor Motifs with Tandem Cysteines
Koray Ütkür, Klaus Mayer, Shihui Liu, et al.
Toxins
|
March 2, 2017
Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins
Klaus Mayer, Anna Schröder, Jerome Schnitger, et al.
FEBS Letters
|
January 18, 2025
Diphthamide synthesis is linked to the eEF2-client chaperone machinery
Lars Kaduhr, Klaus Mayer, Raffael Schaffrath, et al.
Cancer Genomics & Proteomics
|
July 30, 2013
The emerging role of new protein scaffold-based agents for treatment of cancer
Ulrich H Weidle, Johannes Auer, Ulrich Brinkmann, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 97) with videos related to
Sort By:
Page
of 10
Cancer Genomics & Proteomics
|
November 20, 2012
Genetically engineered fusion proteins for treatment of cancer
Ulrich H Weidle, Britta Schneider, Guy Georges, et al.
Cancer Genomics & Proteomics
|
December 28, 2018
The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs
Ulrich H Weidle, Alexandra Epp, Fabian Birzele, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 17, 2015
Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles
Irmgard S Thorey, Michael Grote, Klaus Mayer, et al.
Mabs
|
August 21, 2010
Fluorescent Citrine-IgG fusion proteins produced in mammalian cells
Alexander K Haas, Christoffer von Schwerin, Daniela Matscheko, et al.
Nature Reviews. Drug Discovery
|
March 6, 2024
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M Reichert, et al.
Expert Opinion on Biological Therapy
|
April 23, 2004
Development of secreted proteins as biotherapeutic agents
Angelika L Bonin-Debs, Irene Boche, Hendrik Gille, et al.
Biomolecules
|
April 27, 2024
Functional Integrity of Radical SAM Enzyme Dph1•Dph2 Requires Non-Canonical Cofactor Motifs with Tandem Cysteines
Koray Ütkür, Klaus Mayer, Shihui Liu, et al.
Toxins
|
March 2, 2017
Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins
Klaus Mayer, Anna Schröder, Jerome Schnitger, et al.
FEBS Letters
|
January 18, 2025
Diphthamide synthesis is linked to the eEF2-client chaperone machinery
Lars Kaduhr, Klaus Mayer, Raffael Schaffrath, et al.
Cancer Genomics & Proteomics
|
July 30, 2013
The emerging role of new protein scaffold-based agents for treatment of cancer
Ulrich H Weidle, Johannes Auer, Ulrich Brinkmann, et al.
Page
of 10